Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 101–200 of 1,060

Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L. J., Appel, L. J., Benjamin, E. J., Berra, K. A., Chandra‐Strobos, N., Fabunmi, R. P., Grady, D. G., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Circulation · doi:10.1161/01.cir.0000114834.85476.81 · Cited by 918
Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 930
Stability and Instability: Two Faces of Coronary Atherosclerosis
Davies, M. J. (1996) · Circulation · doi:10.1161/01.cir.94.8.2013 · Cited by 923
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C. T., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S. D., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 933
Primary Prevention of Ischemic Stroke
Goldstein, L. B., Adams, R. J., Becker, K. J., Furberg, C. D., Gorelick, P. B., Hádemenos, G. J., Hill, M., Howard, G., Howard, V. J., Jacobs, B. S., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 902
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori, S. G. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2824 · Cited by 898
Effect of Two Intensive Statin Regimens on Progression of Coronary Disease
Nicholls, S. J., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., Borgman, M., Wolski, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110874 · Cited by 904
Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review
Weitz, J. I., Byrne, J., Clagett, G. P., Farkouh, M. E., Porter, J. M., Sackett, D. L., Strandness, D. E., & Taylor, L. M. (1996) · Circulation · doi:10.1161/01.cir.94.11.3026 · Cited by 884
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 896
Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 844
Identification of Patients at Increased Risk of First Unheralded Acute Myocardial Infarction by Electron-Beam Computed Tomography
Raggi, P., Callister, T. Q., Cooil, B., He, Z.-X., Lippolis, N. J., Russo, D. J., Zelinger, A., & Mahmarian, J. J. (2000) · Circulation · doi:10.1161/01.cir.101.8.850 · Cited by 833
Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)
Wallace, A. M., McMahon, A. D., Packard, C. J., Kelly, A., Shepherd, J., Gaw, A., & Sattar, N. A. (2001) · Circulation · doi:10.1161/hc5001.101061 · Cited by 821
Lipoprotein-Associated Phospholipase A 2 as an Independent Predictor of Coronary Heart Disease
Packard, C. J., O’Reilly, D. S. J., CASLAKE, M. J., McMahon, A. D., Ford, I., Cooney, J., Macphee, C. H., Suckling, K. E., Krishna, M., Wilkinson, F. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431603 · Cited by 822
Statins and cancer prevention
Demierre, M., Higgins, P., Gruber, S. B., Hawk, E. T., & Lippman, S. M. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1751 · Cited by 833
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
McCarey, D. W., McInnes, I. B., Madhok, R., Hampson, R., Scherbakova, O., Ford, I., Capell, H. A., & Sattar, N. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16449-0 · Cited by 814
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 814
Myeloperoxidase and Cardiovascular Disease
Nicholls, S. J., & Hazen, S. L. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000163262.83456.6d · Cited by 805
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11475-1 · Cited by 829
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Electron Beam Computed Tomographic Coronary Calcium Scanning: A Review and Guidelines for Use in Asymptomatic Persons
Rumberger, J. A., Brundage, B. H., Rader, D. J., & Kondos, G. T. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.3.243 · Cited by 796
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790
Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS)
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 792
American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease
O’Rourke, R. A., Brundage, B. H., Froelicher, V. F., Greenland, P., Grundy, S. M., Hachamovitch, R., Pohost, G. M., Shaw, L. J., Weintraub, W. S., Winters, W. L., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00831-7 · Cited by 790
Chronic Heart Failure in the United States
Gheorghiade, M., & Bonow, R. O. (1998) · Circulation · doi:10.1161/01.cir.97.3.282 · Cited by 786
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
Jacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., McKenney, J. M., Grundy, S. M., Gill, E. A., Wild, R. A., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.02.003 · Cited by 781
Peripheral Arterial Disease in the Elderly
Meijer, W. T., Hoes, A. W., Rutgers, D., Bots, M. L., Albert Hofman, D., & Grobbee, D. E. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.2.185 · Cited by 764
Mechanisms and Models in Heart Failure
Mann, D. L. (1999) · Circulation · doi:10.1161/01.cir.100.9.999 · Cited by 769
2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Anderson, T. J., Grégoire, J. C., Hegele, R. A., Couture, P., Mancini, G. B. J., McPherson, R., Francis, G. A., Poirier, P., Lau, D. C. W., Grover, S. A., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.11.032 · Cited by 780
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations
Genest, J. J., McPherson, R., Frohlich, J. J., Anderson, T. J., Campbell, N. R. C., Carpentier, A. C., Couture, P., Dufour, R., Fodor, G. J., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 765
Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality: An Overview of Randomized Trials
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study
Brouilette, S., Moore, J. S., McMahon, A. D., Thompson, J. R., Ford, I., Shepherd, J., Packard, C. J., & Samani, N. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60071-3 · Cited by 747
Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Moss, A. J., Myerburg, R. J., et al. (2006) · EP Europace · doi:10.1093/europace/eul108 · Cited by 741
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Accountability for reasonableness
Daniels, N. (2000) · BMJ · doi:10.1136/bmj.321.7272.1300 · Cited by 729
C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study
Freeman, D. J., Norrie, J. D., CASLAKE, M. J., Gaw, A., Ford, I., Lowe, G. D. O., O’Reilly, D. S. J., Packard, C. J., Sattar, N. A., & for the West of Scotland Coronary Prevention Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.5.1596 · Cited by 727
Low Risk-Factor Profile and Long-term Cardiovascular and Noncardiovascular Mortality and Life Expectancy
Stamler, J., Stamler, R., Neaton, J. D., Wentworth, D. N., Daviglus, M. L., Garside, D., Dyer, A. R., Liu, K., & Greenland, P. (1999) · JAMA · doi:10.1001/jama.282.21.2012 · Cited by 723
Effects of Reconstituted High-Density Lipoprotein Infusions on Coronary Atherosclerosis A Randomized Controlled Trial
Tardif, J. (2007) · JAMA · doi:10.1001/jama.297.15.jpc70004 · Cited by 725
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Graham, I. M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.024 · Cited by 716
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Statins do more than just lower cholesterol
Vaughan, C. J., Murphy, M. B., & Buckley, B. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05190-2 · Cited by 700
The war on cancer
Sporn, M. B. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91015-6 · Cited by 692
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial
Bolland, M. J., Barber, P. A., Doughty, R. N., Mason, B., Horne, A. M., Ames, R. W., Gamble, G. D., Grey, A. B., & Reid, I. R. (2008) · BMJ · doi:10.1136/bmj.39440.525752.be · Cited by 690
Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime
Steinberg, D. H. (2002) · Nature Medicine · doi:10.1038/nm1102-1211 · Cited by 687
Triglyceride Concentration and Ischemic Heart Disease
Jeppesen, J., Hein, H. O., Suadicani, P., & Gyntelberg, F. (1998) · Circulation · doi:10.1161/01.cir.97.11.1029 · Cited by 678
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention
Amarenco, P., & Labreuche, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70058-4 · Cited by 660
Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study
Claudio Napoli, A., Glass, C. K., Witztum, J. L., Deutsch, R., D’Armiento, F. P., & Palinski, W. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02131-5 · Cited by 649
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622
Clinical Pharmacokinetics of Atorvastatin
s, H. L. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 636
Protein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 642
“artery-related diseases using the statin drug [99].”
Primary Prevention of Coronary Heart Disease: Guidance From Framingham: A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction
Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., Houston-Miller, N., Kris-Etherton, P., Krumholz, H. M., LaRosa, J., et al. (1998) · Circulation · doi:10.1161/01.cir.97.18.1876 · Cited by 609
Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health
Fuster, V., & Kelly, B. B. (2010) · Cited by 611
Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study
Ballantyne, C. M., Hoogeveen, R. C., Bang, H., Coresh, J., Folsom, A. R., HEISS, G. M., & Sharrett, A. R. (2004) · Circulation · doi:10.1161/01.cir.0000116763.91992.f1 · Cited by 611
The statins as anticancer agents.
Chan, K., Oza, A. M., & Siu, L. L. (2003) · PubMed · Cited by 607
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting
Natarajan, P., Young, R., Stitziel, N. O., Padmanabhan, S., Baber, U., Mehran, R., Sartori, S., Fuster, V., Reilly, D. F., Butterworth, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024436 · Cited by 570
Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial
Durazzo, A. E. S., Machado, F. S., Ikeoka, D. T., De Bernoche, C., Monachini, M. C., Puech-Leão, P., & Caramelli, B. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.01.004 · Cited by 595
Statins and Cancer Risk
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 600
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
Wang, C., Liu, P., & Liao, J. K. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.11.004 · Cited by 599
Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo
Waßmann, S., Laufs, U., Müller, K., Konkol, C., Ahlbory, K., Bäumer, A. T., Linz, W., Böhm, M., & Nickenig, G. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0202.104081 · Cited by 590
Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)
Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 583
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 573
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis
Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A. (2018) · JAMA · doi:10.1001/jama.2018.2525 · Cited by 549
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia
Marks, D., Thorogood, M., Neil, H. A. W., & Humphries, S. E. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00330-1 · Cited by 575
Endothelial dysfunction in diabetes mellitus.
Hadi, H. A. R., & Suwaidi, J. M. S. A. (2007) · Europe PMC (PubMed Central) · Cited by 568
Statins for Prevention of Cardiovascular Disease in Adults
Chou, R., Dana, T., Blazina, I., Daeges, M., & Jeanne, T. L. (2016) · JAMA · doi:10.1001/jama.2015.15629 · Cited by 570
RAGE Blockade Stabilizes Established Atherosclerosis in Diabetic Apolipoprotein E–Null Mice
Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E., Rong, L., Goova, M. T., Moser, B., Kislinger, T., Lee, D. C., et al. (2002) · Circulation · doi:10.1161/01.cir.0000039325.03698.36 · Cited by 562
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 558
Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target
Golia, E., Limongelli, G., Natale, F., Fimiani, F., Maddaloni, V., Pariggiano, I., Bianchi, R., Crisci, M., D’Acierno, L., Giordano, R. C., et al. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0435-z · Cited by 572
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
Taylor, A. J., Kent, S. M., Flaherty, P. J., Coyle, L. C., Markwood, T. T., & Vernalis, M. (2002) · Circulation · doi:10.1161/01.cir.0000034508.55617.65 · Cited by 555
The Unstable Atheroma
Lee, R. T., & Libby, P. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.10.1859 · Cited by 557
Lipid Lowering by Diet Reduces Matrix Metalloproteinase Activity and Increases Collagen Content of Rabbit Atheroma
Aikawa, M., Aïkawa, E., Okada, Y., Voglic, S. J., Clinton, S. K., Brinckerhoff, C., Sukhova, G. K., & Libby, P. (1998) · Circulation · doi:10.1161/01.cir.97.24.2433 · Cited by 552
Is atrial fibrillation an inflammatory disorder?
Boos, C. J., Anderson, R. A., & Lip, G. Y. H. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi645 · Cited by 552
Untitled work
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Critical Issues in Peripheral Arterial Disease Detection and Management A Call to Action
Belch, J. J. F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.8.884 · Cited by 569
Improving Coronary Heart Disease Risk Assessment in Asymptomatic People
Greenland, P., Smith, S. C., & Grundy, S. M. (2001) · Circulation · doi:10.1161/hc4201.097189 · Cited by 558
Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community
Melander, O. (2009) · JAMA · doi:10.1001/jama.2009.943 · Cited by 549
A historical perspective on the discovery of statins
Endo, A. (2010) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.86.484 · Cited by 550
Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn‐Alloys
Bowen, P. K., Shearier, E. R., Zhao, S., Guillory, R. J., Zhao, F., Goldman, J., & Drelich, J. W. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201501019 · Cited by 546
The endotoxin-lipoprotein hypothesis
Rauchhaus, M., Coats, A. J. S., & Anker, S. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02690-8 · Cited by 544
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
Austin, M. A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh236 · Cited by 657
Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
Grundy, S. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00033-2 · Cited by 525
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors: Similarities and Differences
Lennernäs, H., & Fager, G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732050-00005 · Cited by 527
Trends in Serum Lipids and Lipoproteins of Adults, 1960-2002
Carroll, M. D. (2005) · JAMA · doi:10.1001/jama.294.14.1773 · Cited by 533
The Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, T. C. G., Richel, D. J., & Guchelaar, H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 530
Statin effects beyond lipid lowering—are they clinically relevant?
Bonetti, P. O. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00419-0 · Cited by 526
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA)
Sever, P., Dahl??f, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2004) · Drugs · doi:10.2165/00003495-200464002-00005 · Cited by 525
Adolescent Overweight and Future Adult Coronary Heart Disease
Bibbins-Domingo, K. B., Coxson, P. G., Pletcher, M. J., Lightwood, J. M., & Goldman, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa073166 · Cited by 529
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death—executive summary
Zipes, D. P., Camm, A. J., Borggrefe, M. M., Buxton, A. E., CHAITMAN, B. R., FROMER, M. A., Gregoratos, G., Klein, G. J., Moss, A. J., Myerburg, R. J., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl199 · Cited by 519
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., Boven, A. J. V., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 518
Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations
Tunstall‐Pedoe, H., Vanuzzo, D., HOBBS, M. S. T., Mähönen, M., Čepaitis, Ž., Kuulasmaa, K., & Keil, U. (2000) · The Lancet · doi:10.1016/s0140-6736(99)11181-4 · Cited by 515
HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages
Bellosta, S., Via, D. P., Canavesi, M., Pfister, P., Fumagalli, R., Paoletti, R., & Bernini, F. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.11.1671 · Cited by 512
American College of Cardiology/American Heart Association Expert Consensus Document on Electron-Beam Computed Tomography for the Diagnosis and Prognosis of Coronary Artery Disease
O’Rourke, R. A., Brundage, B. H., Froelicher, V. F., Greenland, P., Grundy, S. M., Hachamovitch, R., Pohost, G. M., Shaw, L. J., Weintraub, W., Winters, W. L., et al. (2000) · Circulation · doi:10.1161/01.cir.102.1.126 · Cited by 506
Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement
Heber, D., Yip, I., Ashley, J. M., Elashoff, D. A., Elashoff, R. M., & Go, V. L. W. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.2.231 · Cited by 499
Social capital and health: Implications for public health and epidemiology
Lomas, J. (1998) · Social Science & Medicine · doi:10.1016/s0277-9536(98)00190-7 · Cited by 500
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors
Schönbeck, U., & Libby, P. (2004) · Circulation · doi:10.1161/01.cir.0000129505.34151.23 · Cited by 500

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks